12/11
09:04 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/11
05:42 am
mirm
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback [Yahoo! Finance]
12/10
07:00 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/10
05:04 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Leerink Partners.
12/10
05:03 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $100.00 price target on by analysts at Leerink Partners.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $100.00 price target on by analysts at Leerink Partners.
12/9
09:11 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/8
07:00 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $88.00 price target on by analysts at Robert W. Baird.
Medium
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $88.00 price target on by analysts at Robert W. Baird.
12/8
06:07 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
Medium
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Evercore ISI.
12/8
11:01 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
12/8
08:00 am
mirm
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
Low
Report
Mirum Pharmaceuticals Enters into Definitive Agreement to Acquire Bluejay Therapeutics, Expanding Global Leadership in Rare Disease
12/5
05:43 am
mirm
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) [Yahoo! Finance]
Medium
Report
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) [Yahoo! Finance]
12/2
04:26 pm
mirm
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
12/1
08:10 am
mirm
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Medium
Report
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
11/25
04:24 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
11/25
04:02 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
11/10
08:00 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/7
08:40 am
mirm
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting® [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting® [Yahoo! Finance]
11/7
08:10 am
mirm
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
Low
Report
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
11/5
10:03 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/5
08:07 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Citizens Jmp from $81.00 to $95.00. They now have a "market outperform" rating on the stock.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Citizens Jmp from $81.00 to $95.00. They now have a "market outperform" rating on the stock.
11/5
08:04 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $95.00 price target on by analysts at JMP Securities.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $95.00 price target on by analysts at JMP Securities.
11/5
07:19 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
11/5
07:19 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/4
04:01 pm
mirm
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
04:05 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences